Brain Dopaminergic Signaling in Opioid Use Disorders
Public ClinicalTrials.gov record NCT03190954. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Brain Dopaminergic Signaling in Opioid Use Disorders (OUD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Background: The chemical messenger dopamine carries signals between brain cells. It may affect addiction. Heavy use of pain medicines called opioids may decrease the amount of dopamine available to the brain. Researchers want to study if decreased dopamine decreases self-control and increases impulsiveness. Objective: To learn more about how opiate use disorder affects dopamine in the brain. Eligibility: Adults 18-80 years old who are moderate or severe opiate users Healthy volunteers the same age Design: Participants will first be screened under another protocol. They will: * Have a physical exam * Answer questions about their medical, psychiatric, and alcohol and drug use history * Take an MRI screening questionnaire * Give blood and urine samples * Have their breath tested for alcohol Participants will have up to 3 study visits. They will have 2-3 positron emission tomography (PET) scans. A radioactive chemical will be injected for the scans. Participants will lie on a bed that slides in and out of the donut-shaped scanner. A cap or plastic mask may be placed on the head. Vital signs will be taken before and after the PET scans. Participants will get capsules of placebo or the study drug. They will rate how they feel before, during and after. Participants will have their breath and urine tested each day. Participants will have magnetic resonance imaging (MRI) scans. They will lie on a table that slides into a cylinder in a strong magnetic field. They may do tasks on a computer screen while inside the scanner. Participants will have tests of memory, attention, and thinking. Participants will wear an activity monitor for one week.
Study identification
- NCT ID
- NCT03190954
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 153 participants
Conditions and interventions
Conditions
Interventions
- [11C]raclopride plus placebo Drug
- [11C]raclopride plus drug Drug
- [11C]NNC-112 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 16, 2017
- Primary completion
- Oct 26, 2025
- Completion
- Oct 26, 2025
- Last update posted
- Aug 31, 2026
2017 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Normal Physiology trials
Other public records listing Normal Physiology. Sorted by last update posted; newest first. Not a recommendation.
- NCT01324206: Development of 3T Magnetic Resonance Research Methods for NIA Studies Recruiting
- NCT03258580: Sociocultural & Biobehavioral Influences on Pain Expression and Assessment Recruiting
- NCT05604534: Assessing and Improving Quantitative Magnetic Resonance Imaging Metrics in Human Subjects Recruiting
- NCT02629107: Functional Magnetic Resonance Imaging Sleep Study With Auditory Stimuli Recruiting
- NCT05666739: NIEHS Repository of Stored Biological Samples for Future Use Recruiting
- NCT03407066: Perception, Sensation, Cognition and Action in Humans Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03190954, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03190954 live on ClinicalTrials.gov.